Johnson and Johnson 2009 Annual Report Download - page 6

     
JOHNSON & JOHNSON 2009 ANNUAL REPORT4
experienced an operational sales decline of . percent in ,
reecting the loss of nearly $ billion in sales due to losing market
exclusivity for
® (risperidone) and ®
(topiramate).Excluding the impact of generic competition,
pharmaceutical sales increased by approximately  percent
operationally.
This growth was driven by larger products, including
® (iniximab), for the treatment of a number of
immune-mediated inammatory diseases;
®
(methylphenidate HCl) Extended-release Tablets in attention
deficit hyperactivity disorder (ADHD); and
®
® (risperidone) Long-Acting Injection, an atypical
antipsychotic administered every two weeks for the treatment
of schizophrenia or the maintenance of bipolar  disorder.
Promising newer products continued their positive growth
trajectory, such as
® (darunavir) in HIV; ®
(bortezomib), for multiple myeloma, developed in partnership
with Millennium: The Takeda Oncology Company (we have rights
outside the U.S.);
® (paliperidone), a once-daily atypical
antipsychotic for the treatment of schizophrenia or acute
schizoaective disorder; and
™ (etravirine), for
HIV combination therapy.
Our pharmaceutical pipeline is one of the most robust in our
history.We launched five newly approved drugs in :
™ (golimumab) and ™ (ustekinumab) in
immunology;
® (tapentadol) Immediate Release
Tablets for pain relief and
® ™ (paliperidone
palmitate) for the treatment of schizophrenia; and
™
(dapoxetine) in select countries across the world in sexual health.
In addition, we continue to expand our core products with new
indications, a practice we have done well historically. For example,
® now has  FDA-approved indications across a broad
spectrum of immune system disorders.
Our future pipeline is promising. An important product in
registration is rivaroxaban, which we are co-developing with Bayer
HealthCare AG.Rivaroxaban is a novel oral anticoagulant that
may prevent a host of thrombotic conditions, including venous
thromboembolism and stroke in atrial fibrillation.It is being
evaluated in five dierent indications.And we have important
compounds in Phase III clinical trials, including treatments for
diabetes, prostate cancer and Alzheimer’s disease.
Building on our already strong pipeline, we engaged in
acquisitions and innovative agreements and collaborations with
companies that oer potentially significant advances in patient
care.These include a potential first-in-class treatment for slowing
the progression of Alzheimer’s disease (Elan Corporation, plc);
a potential universal monoclonal antibody product for the
treatment and prevention of inuenza (Crucell NV); an HIV
therapy with a single combination pill (Gilead Sciences, Inc.);
and a potential breakthrough in prostate cancer (Cougar
Biotechnology, Inc.).
While strengthening its pipeline, our Pharmaceuticals business
expanded geographically, with a focus on emerging markets.We
have been expanding our sales reach in China; maintaining a
strong manufacturing footprint in China, Mexico and Brazil; and
developing our R&D presence in emerging markets like India and
China by establishing an R&D operation in Mumbai, an R&D head-
quarters in Shanghai and a collaboration with Tianjin Medical
University Cancer Hospital on biomarker research.

(in billions of dollars)
2009 Sales: $22.5 billion
Sales Change
Total: (8.3%)
Operational*: (6.1%)
LEVAQUIN®/
FLOXIN®
$1.6
(2.6%)
REMICADE®
$4.3
14.8%
PROCRIT®/
EPREX®
$2.2
(8.7%)
RISPERDAL®
$0.9
(57.7%)
RISPERDAL®
CONSTA®
$1.4
8.9%
CONCERTA®
$1.3
6.3%
OTHER
$7.6
6.6%
DURAGESIC®
$0.9
(14.3%)
ACIPHEX®/PARIET®
$1.1
(5.4%)
TOPAMAX®
$1.2
(57.9%)


(in billions of dollars)
2009 Sales: $23.6 billion
Sales Change
Total: 1.9%
Operational*: 4.2%
DEPUY®
$5.4
4.6%
ETHICON
ENDO-SURGERY®
$4.5
4.8%
DIABETES
CARE
$2.4
(3.7%)
ORTHO-CLINICAL
DIAGNOSTICS®
$2.0
6.6%
VISION
CARE
$2.5
0.2%
CORDIS®
$2.7
(10.3%)
ETHICON®
$4.1
7.3%

(in billions of dollars)
2009 Sales: $15.8 billion
Sales Change
Total: (1.6%)
Operational*: 2.0%
SKIN CARE
$3.5
2.5%
OTC
PHARMACEUTICALS
& NUTRITIONALS
$5.6
(4 . 5 %)
BABY CARE
$2.1
(4.5%)
WOUND
CARE/
OTHER
$1.1
9.4%
ORAL CARE
$1.6
(3.4%)
WOMEN’S
HEALTH
$1.9
(0.8%)
* Operational excludes the impact of currency